We are live on
!
Find out more
Ensign Peak Advisors Portfolio holdings
AUM
$53.7B
1-Year Est. Return
29.47%
This Fund
S&P 500
This Quarter
Est. Return
+8.8%
1 Year Est. Return
+29.47%
3 Year Est. Return
+102.45%
5 Year Est. Return
+139.11%
10 Year Est. Return
–
AUM
$46.2B
AUM Growth
+$1.83B
(+4.1%)
Cap. Flow
-$543M
Cap. Flow
% of AUM
-1.17%
Top 10 Holdings %
Top 10 Hldgs %
24.86%
Holding
1,809
New
24
Increased
1,140
Reduced
325
Closed
37
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$98M |
| 2 |
Kinder Morgan
KMI
|
+$97.7M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$96.6M |
| 4 |
UnitedHealth
UNH
|
+$77.5M |
| 5 |
Marriott International
MAR
|
+$58.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FRC
First Republic Bank
FRC
|
+$198M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$179M |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$162M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$154M |
| 5 |
Bank of America
BAC
|
+$112M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.89% |
| 2 | Healthcare | 18.49% |
| 3 | Financials | 11.85% |
| 4 | Consumer Discretionary | 9.1% |
| 5 | Industrials | 7.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Littelfuse
LFUS
$9.91B
| $25.9M | 0.06% |
96,597
+7,038
| +8% | +$1.81M |
|
252
Sarepta Therapeutics
SRPT
$1.63B
| $25.8M | 0.06% |
187,345
+39,985
| +27% | +$5.19M |
|
253
Freeport-McMoran
FCX
$88.6B
| $25.7M | 0.06% |
628,439
+214,451
| +52% | +$8.92M |
|
|
KRTX
254
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $25.7M | 0.06% |
141,315
| – | – |
|
255
Conagra Brands
CAG
$7.38B
| $25.5M | 0.06% |
678,423
-44,720
| -6% | -$1.66M |
|
256
VeriSign
VRSN
$25.4B
| $25.4M | 0.05% |
120,179
-677
| -0.6% | -$140K |
|
257
Williams Companies
WMB
$85.8B
| $25.3M | 0.05% |
848,458
+4,270
| +0.5% | +$132K |
|
258
Dorman Products
DORM
$4.28B
| $25.2M | 0.05% |
292,300
+14,600
| +5% | +$1.3M |
|
259
TE Connectivity
TEL
$62.1B
| $25.2M | 0.05% |
191,866
-22
| -0% | -$2.78K |
|
260
Okta
OKTA
$23.7B
| $24.1M | 0.05% |
280,007
-25,594
| -8% | -$1.95M |
|
261
RB Global
RBA
$21.7B
| $23.6M | 0.05% |
419,917
+23,561
| +6% | +$1.39M |
|
|
PPL
262
PPL Corp
PPL
$27.3B
| $23.6M | 0.05% |
849,342
-407,267
| -32% | -$11.5M |
|
263
Constellation Energy
CEG
$92.8B
| $23.3M | 0.05% |
296,942
-7,505
| -2% | -$607K |
|
264
Extra Space Storage
EXR
$32.2B
| $23.2M | 0.05% |
142,215
-11,472
| -7% | -$1.8M |
|
265
Moderna
MRNA
$22.1B
| $22.9M | 0.05% |
149,052
+29,110
| +24% | +$4.8M |
|
266
Idexx Laboratories
IDXX
$44.9B
| $22.9M | 0.05% |
45,722
+2,087
| +5% | +$999K |
|
267
Dow Inc
DOW
$20.8B
| $22.5M | 0.05% |
409,687
-64,934
| -14% | -$3.65M |
|
268
Best Buy
BBY
$18.9B
| $22.4M | 0.05% |
285,703
+54,885
| +24% | +$4.52M |
|
269
Amphenol
APH
$177B
| $22.2M | 0.05% |
542,912
+168,196
| +45% | +$6.64M |
|
270
Capital One
COF
$130B
| $22.1M | 0.05% |
229,538
-89,180
| -28% | -$9.33M |
|
271
HealthEquity
HQY
$8.46B
| $21.9M | 0.05% |
373,807
+17,352
| +5% | +$1.05M |
|
272
Corebridge Financial
CRBG
$14.6B
| $21.9M | 0.05% |
1,364,258
+1,266,046
| +1,289% | +$24.8M |
|
273
DexCom
DXCM
$28.9B
| $21.8M | 0.05% |
187,690
+3,427
| +2% | +$384K |
|
274
Travelers Companies
TRV
$82.9B
| $21.5M | 0.05% |
125,496
-7,880
| -6% | -$1.43M |
|
275
IDEX
IEX
$16.6B
| $21.3M | 0.05% |
92,241
-107
| -0.1% | -$24.3K |
|
Similar funds
SCP
Ensign Peak Advisors's Q1 2023 Portfolio in Review
As of Q1 2023, Ensign Peak Advisors held 1,809 positions worth $46.2B, up 4.1% from $44.4B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Trading was light in Q1 2023: portfolio turnover was 3.4%. Ensign Peak Advisors opened 24 new positions and exited 37, leaving the 1,809-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
- Ensign Peak Advisors's largest Q1 2023 buy was State Street Financial Select Sector SPDR ETF: 1,117,296 shares worth $35.9M.
- Ensign Peak Advisors added most to Eli Lilly in Q1 2023, an estimated $98M increase.
- Ensign Peak Advisors's biggest Q1 2023 reduction was First Republic Bank, cutting an estimated $198M.
- Ensign Peak Advisors fully exited iShares Russell 2000 ETF in Q1 2023, selling an estimated $179M.
- Ensign Peak Advisors's ten largest holdings make up 25% of its $46.2B portfolio in Q1 2023.
- Ensign Peak Advisors opened 24 new positions and closed 37 in Q1 2023.
- Ensign Peak Advisors's portfolio value rose 4.1% quarter-over-quarter to $46.2B.
Based on Ensign Peak Advisors's 13F filing for Q1 2023, filed 15 May 2023.